A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.

PLoS Negl Trop Dis

Laboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.

Published: April 2015

Background: Lassa virus (LASV) is endemic in several West African countries and is the etiological agent of Lassa fever. Despite the high annual incidence and significant morbidity and mortality rates, currently there are no approved vaccines to prevent infection or disease in humans. Genetically, LASV demonstrates a high degree of diversity that correlates with geographic distribution. The genetic heterogeneity observed between geographically distinct viruses raises concerns over the potential efficacy of a "universal" LASV vaccine. To date, several experimental LASV vaccines have been developed; however, few have been evaluated against challenge with various genetically unique Lassa virus isolates in relevant animal models.

Methodologies/principle Findings: Here we demonstrate that a single, prophylactic immunization with a recombinant vesicular stomatitis virus (VSV) expressing the glycoproteins of LASV strain Josiah from Sierra Leone protects strain 13 guinea pigs from infection / disease following challenge with LASV isolates originating from Liberia, Mali and Nigeria. Similarly, the VSV-based LASV vaccine yields complete protection against a lethal challenge with the Liberian LASV isolate in the gold-standard macaque model of Lassa fever.

Conclusions/significance: Our results demonstrate the VSV-based LASV vaccine is capable of preventing morbidity and mortality associated with non-homologous LASV challenge in two animal models of Lassa fever. Additionally, this work highlights the need for the further development of disease models for geographical distinct LASV strains, particularly those from Nigeria, in order to comprehensively evaluate potential vaccines and therapies against this prominent agent of viral hemorrhagic fever.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401668PMC
http://dx.doi.org/10.1371/journal.pntd.0003736DOI Listing

Publication Analysis

Top Keywords

lassa fever
12
lasv vaccine
12
lasv
11
recombinant vesicular
8
vesicular stomatitis
8
guinea pigs
8
lassa virus
8
morbidity mortality
8
infection disease
8
vsv-based lasv
8

Similar Publications

Introduction: Lassa fever (LF), a public health problem of great importance endemic in West Africa, is an acute and sometimes fatal viral haemorrhagic disease which leads to mortality. The current study assessed the knowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.

Methods: Descriptive study design and Cross sectional study design was used for this study.

View Article and Find Full Text PDF

Current perspectives on vaccines and therapeutics for Lassa Fever.

Virol J

December 2024

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.

View Article and Find Full Text PDF

Descriptive epidemiology of Lassa fever, its trend, seasonality, and mortality predictors in Ebonyi State, South- East, Nigeria, 2018-2022.

BMC Public Health

December 2024

Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria.

Background: Nigeria is an epicenter for Lassa fever. Ebonyi state is located in the South-Eastern region of Nigeria where a high burden of Lassa fever has been reported. Therefore, this study was designed to assess the epidemiology of Lassa fever, its seasonality, trend, and mortality predictors in Ebonyi state, South-East, Nigeria.

View Article and Find Full Text PDF

Systematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.

Am J Trop Med Hyg

December 2024

Department of Medicine, Section of Infectious Diseases, School of Medicine, Tulane University, New Orleans, Louisiana.

Article Synopsis
  • The systematic review focuses on reproductive health issues faced by female survivors of Lassa fever and Ebola virus disease.
  • Thirteen studies reviewed predominantly highlight negative outcomes related to reproductive health among EVD survivors, including menstrual irregularities and pregnancy loss, with no research identified on LF survivors.
  • The analysis indicates that about 14% of female EVD survivors experience adverse reproductive health outcomes, revealing a significant need for further research in this area.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!